Binding affinities of mozavaptan hydrochloride (OPC-31260) for vasopressin receptors

Japanese Pharmacology and Therapeutics

Volumn 34, Issue 7, 2006, Pages 827-834

  Nakamura, Shigeki ^a   Itoh, Shuji ^a   Fujiki, Hiroyuki ^a   Yamamura, Yoshitaka ^a   Mori, Toyoki ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Binding affinity; Mozavaptan hydrochloride; Vasopressin V 2 receptor antagonist

Indexed keywords

ARGIPRESSIN; CYCLIC AMP; MOZAVAPTAN; RECEPTOR SUBTYPE; VASOPRESSIN RECEPTOR;

ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; HORMONE ACTION; HORMONE BINDING; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION;

EID: 33749468001     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. 1a arginine vasopressin receptor. Nature 1992; 356: 523-6.
2. Birnbaumer M, Seibold A, Gilbert S, Ishido M, Barberis C, Antaramian A, et al. Molecular cloning of the receptor for human antidiuretic hormone. Nature 1992; 357: 333-5.
3. 1b vasopressin receptor. J Biol Chem 1994; 269: 27088-92.
4. Schrier RW. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 1988; 319: 1065-72.
5. Erratum in: N Engl J Med 1989; 320: 676.
6. Goldsmith SR, Dodge-Brown DL, Katz A. Alpha 2-adrenergic stimulation and vasopressin in congestive heart failure. J Cardiovasc Pharmacol 1989; 14: 425-9.
7. Manning M, Sawyer WH. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J Lab Clin Med 1989; 114: 617-32.
8. Erratum in: J Lab Clin Med 1990; 115: 530.
9. Dubb J, Allison N, Tatoian D, Blumberg A, Lee K, Stote R. SK & F 101926 is antidiuretic in man. Kidney Int 1987; 31 (abstract): 267.
10. Brooks DP, Koster PF, Albrightson-Winslow CR, Stassen FL, Huffman WF, Kinter LB. SK & F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatta). J Pharmacol Exp Ther 1988; 245: 211-5.
11. 1 antagonists. A novel series of 1- (1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone. J Med Chem 1993; 36: 2011-7.
12. 2 receptor antagonist. Br J Pharmacol 1992; 105: 787-91.
13. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
14. Nakamura T, Tomomura A, Noda C, Shimoji M, Ichihara A. Acquisition of a beta-adrenergic response by adult rat hepatocytes during primary culture. J Biol Chem 1983; 258: 9283-9.
15. Khanna AS, Agrawal AK, Seth PK. 3H-spiroperidol binding sites in blood platelets. Biochem Biophys Res Commun 1987; 146: 983-8.
16. Durrieu G, Valet P, Berlan M, Villeneuve A, Montastruc JL. Levodopa up-regulates platelet alpha 2-adrenoceptors. Eur J Pharmacol 1990; 182: 597-601.
17. Nakahara T, Terada S, Pincus J, Flouret G, Hechter O. Neurohypophyseal hormone-responsive renal adenylate cyclase. I: general characteristics of the neurohypophyseal hormone-sensitive adenylate cyclase in bovine renal medullary membranes prepared using a double phase polymer system. J Biol Chem 1978; 253: 3211-8.
18. 50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-108.
19. Mah SC, Hofbauer KG. Evaluation of the pharmacologic properties of a vasopressin antagonist in Brattleboro rats. J Pharmacol Exp Ther 1988; 245: 1028-32.
20. 2 antagonist in men. J Pharmacol Exp Ther 1995; 272: 546-51.
21. Erratum in: J Pharmacol Exp Ther 1995; 274: 1573.